Endoglin (CD105): A marker of tumor vasculature and potential target for therapy

Clinical Cancer Research

Volumn 14, Issue 7, 2008, Pages 1931-1937

  Dallas, Nikolaos A ^a   Samuel, Shaija ^a   Xia, Ling ^a   Fan, Fan ^a   Gray, Michael J ^a   Lim, Sherry J ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ENDOGLIN; EPIRUBICIN; FLUOROURACIL; TECHNETIUM 99M; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; BREAST CANCER; CELL PROLIFERATION; GENE MUTATION; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENDU OSLER WEBER DISEASE; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS, CD; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 42249110348     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4478     Document Type: Review

References (69)

1. Letamendia A, Lastres P, Botella LM, et al. Role of endoglin in cellular responses to transforming growth factor-β. A comparative study with betaglycan. J Biol Chem1998;273:33011-9.
2. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem 1999;274:584-94.
3. Fonsatti E, Del Vecchio L, Altomonte M, et al. Endoglin: an accessory component of the TGF-β-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001;188:1-7.
4. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med 2004;2:18.
5. Lastres P, Letamendia A, Zhang H, et al. Endoglin modulates cellular responses to TGF-β1. J Cell Biol 1996;133:1109-21.
6. Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets 2003;3:427-32.
7. Rius C, Smith JD, Almendro N, et al. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 1998;92:4677-90.
8. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003;17:984-92.
9. Cheifetz S, Bellon T, Cales C, et al. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992;267:19027-30.
10. Bobik A. Transforming growth factor-βs and vascular disorders. Arterioscler Thromb Vasc Biol 2006;26:1712-20.
11. Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-β signal transduction in angiogenesis and vascular disorders. Chest 2005;128:585-90S.
12. Santibanez JF, Letamendia A, Perez-Barriocanal F, et al. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-β signaling. J Cell Physiol 2007;210:456-68.
13. Lebrin F, Deckers M, Bertolino P, ten Dijke P. TGF-β receptor function in the endothelium. Cardiovasc Res 2005;65:599-608.
14. Arthur HM, Ure J, Smith AJ, et al. Endoglin, an ancillary TGFβ receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000;217:42-53.
15. Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science 1999;284:1534-7.
16. Govinden R, Bhoola KD. Genealogy, expression, and cellular function of transforming growth factor-β. Pharmacol Ther 2003;98:257-65.
17. Koleva RI, Conley BA, Romero D, et al. Endoglin structure and function: determinants of endoglin phosphorylation by transforming growth factor-β receptors. J Biol Chem 2006;281:25110-23.
18. Scharpfenecker M, van Dinther M, Liu Z, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007;120:964-72.
19. Mercado-Pimentel ME, Hubbard AD, Runyan RB. Endoglin and Alk5 regulate epithelial-mesenchymal transformation during cardiac valve formation. Dev Biol 2007;304:420-32.
20. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor β1 on human vascular endothelial cells. FASEB J 2000;14:55-64.
21. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-β receptor signalling and turnover. Nat Cell Biol 2003;5:410-21.
22. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J 2002;21:1743-53.
23. Gajdusek CM, Luo Z, Mayberg MR. Basic fibroblast growth factor and transforming growth factor β-1: synergistic mediators of angiogenesis in vitro. J Cell Physiol 1993;157:133-44.
24. Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-β1 on in vitro angiogenesis. Exp Cell Res 1993;204:356-63.
25. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-β receptor complex. J Cell Physiol 2005;204:574-84.
26. Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J 2004;23:4018-28.
27. Lux A, Salway F, Dressman HK, et al. ALK1 signalling analysis identifies angiogenesis related genes and reveals disparity between TGF-β and constitutively active receptor induced gene expression. BMC Cardiovasc Disord 2006;6:13.
28. Guo B, Slevin M, Li C, et al. CD105 inhibits transforming growth factor-β-Smad3 signalling. Anticancer Res 2004;24:1337-45.
29. Guo B, Kumar S, Li C, Slevin M, Kumar P. CD105 (endoglin), apoptosis, and stroke. Stroke 2004;35:e94-5.
30. Li C, Issa R, Kumar P, et al. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 2003;116:2677-85.
31. Warrington K, Hillarby MC, Li C, Letarte M, Kumar S. Functional role of CD105 in TGF-β1 signalling in murine and human endothelial cells. Anticancer Res 2005;25:1851-64.
32. Pece-Barbara N, Vera S, Kathirkamathamby K, et al. Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor β1 with higher affinity receptors and an activated Alk1 pathway. J Biol Chem 2005;280:27800-8.
33. Jerkic M, Rivas-Elena JV, Prieto M, et al. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 2004;18:609-11.
34. Toporsian M, Gros R, Kabir MG, et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005;96:684-92.
35. Kumar P, Wang JM, Bernabeu C. CD105 and angiogenesis. J Pathol 1996;178:363-6.
36. Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O. Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int 2006;56:717-23.
37. Yu JX, Cui L, Zhang QY, et al. Expression of NOS and HIF-1α in human colorectal carcinoma and implication in tumor angiogenesis. World J Gastroenterol 2006;12:4660-4.
38. Ding S, Li C, Lin S, et al. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol 2006;37:861-6.
39. Nikiteas NI, Tzanakis N, Theodoropoulos G, et al. Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer 2007;10:12-7.
40. Saad RS, El-Gohary Y, Memari E, Liu YL, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol 2005;36:955-61.
41. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 2004;17:197-203.
42. Akagi K, Ikeda Y, Sumiyoshi Y, et al. Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 2002;131:S109-13.
43. Gomez-Esquer F, Agudo D, Martinez-Arribas F, Nunez-Villar MJ, Schneider J. mRNA expression of the angiogenesis markers VEGF and CD105 (endoglin) in human breast cancer. Anticancer Res 2004;24:1581-5.
44. Li C, Guo B, Wilson PB, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 2000;89:122-6.
45. Beresford MJ, Harris AL, Ah-See M, Daley F, Padhani AR, Makris A. The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer 2006;95:1683-8.
46. Yang LY, Lu WQ, Huang GW, Wang W. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 2006;6:110.
47. El-Gohary YM, Silverman JF, Olson PR, et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 2007;127:572-9.
48. Chien CY, Su CY, Hwang CF, Chuang HC, Chen CM, Huang CC. High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis. J Surg Oncol 2006;94:413-7.
49. Chuang HC, Su CY, Huang HY, Chien CY, Chen CM, Huang CC. High expression of CD105 as a prognostic predictor of early tongue cancer. Laryngoscope 2006;116:1175-9.
50. Marioni G, Marino F, Giacomelli L, et al. Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma. Acta Otolaryngol 2006;126:633-9.
51. Behrem S, Zarkovic K, Eskinja N, Jonjic N. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma. Croat Med J 2005;46:417-22.
52. Yao Y, Kubota T, Takeuchi H, Sato K. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 2005;25:201-6.
53. Erdem O, Taskiran C, Onan MA, Erdem M, Guner H, Ataoglu O. CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecol Oncol 2006;103:1007-11.
54. Taskiran C, Erdem O, Onan A, et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer 2006;16:1789-93.
55. Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA. Hypoxic induction of endoglin via mitogen-activated protein kinases inmouse brain microvascular endothelial cells. Stroke 2003;34:2483-8.
56. m-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer 2004;109:436-41.
57. Fonsatti E, Jekunen AP, Kairemo KJ, et al. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 2000;6:2037-43.
58. Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R. Imaging of tumour neovasculature by targeting the TGF-β binding receptor endoglin. Eur J Cancer 2000;36:675-81.
59. Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 2007;13:323-30.
60. Duwel A, Eleno N, Jerkic M, et al. Reduced tumor growth and angiogenesis in endoglin-haploinsufficient mice. Tumour Biol 2007;28:1-8.
61. She X, Matsuno F, Harada N, Tsai H, Seon BK. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-β in suppression of growth of human endothelial cells. Int J Cancer 2004;108:251-7.
62. Tsujie M, Uneda S, Tsai H, Seon BK. Effective antiangiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites. Int J Oncol 2006;29:1087-94.
63. Shiozaki K, Harada N, Greco WR, et al. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. Cancer Immunol Immunother 2006;55:140-50.
64. 125I-labeled anti-endoglin monoclonal antibodies. Int J Cancer 1999;82:737-42.
65. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999;5:371-82.
66. Nettelbeck DM, Miller DW, Jerome V, et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 2001;3:882-91.
67. Volkel T, Holig P, Merdan T, Muller R, Kontermann RE. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 2004;1663:158-66.
68. Lee SH, Mizutani N, Mizutani M, et al. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol Immunother 2006;55:1565-74.
69. Maio M, Altomonte M, Fonsatti E. Is it the primetime for endoglin (CD105) in the clinical setting? Cardiovasc Res 2006;69:781-3.